Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s What Happened

Posted by Brian Himes on May 28th, 2026

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $11.10, but opened at $11.80. Design Therapeutics shares last traded at $10.84, with a volume of 39,548 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Design Therapeutics in a research note on Monday, April 20th. Cantor Fitzgerald assumed coverage on Design Therapeutics in a research note on Tuesday, May 12th. They issued an “overweight” rating on the stock. Royal Bank Of Canada boosted their target price on Design Therapeutics from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Jefferies Financial Group assumed coverage on Design Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $15.00 target price on the stock. Finally, Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Get Our Latest Report on Design Therapeutics

Design Therapeutics Price Performance

The stock has a market cap of $670.51 million, a PE ratio of -8.93 and a beta of 1.73. The business has a 50 day simple moving average of $12.29 and a 200 day simple moving average of $10.51.

Design Therapeutics (NASDAQ:DSGN – Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.07. As a group, sell-side analysts forecast that Design Therapeutics, Inc. will post -1.36 earnings per share for the current fiscal year.

Institutional Trading of Design Therapeutics

Several large investors have recently made changes to their positions in DSGN. Vivo Capital LLC bought a new stake in shares of Design Therapeutics during the 4th quarter worth about $15,129,000. RA Capital Management L.P. increased its stake in shares of Design Therapeutics by 207.2% in the fourth quarter. RA Capital Management L.P. now owns 1,461,381 shares of the company’s stock worth $13,708,000 after purchasing an additional 985,682 shares during the period. Woodline Partners LP bought a new stake in Design Therapeutics during the 1st quarter valued at approximately $2,492,000. Baker BROS. Advisors LP boosted its stake in Design Therapeutics by 30.4% during the 4th quarter. Baker BROS. Advisors LP now owns 2,233,099 shares of the company’s stock valued at $20,946,000 after purchasing an additional 520,217 shares during the period. Finally, Invesco Ltd. boosted its stake in Design Therapeutics by 1,995.8% during the 4th quarter. Invesco Ltd. now owns 305,757 shares of the company’s stock valued at $2,868,000 after purchasing an additional 291,168 shares during the period. Institutional investors own 56.64% of the company’s stock.

About Design Therapeutics

(Get Free Report)

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.